A new family of densely functionalized fused-benzoquinones as potent human protein kinase CK2 inhibitors

P Martin-Acosta, S Haider, A Amesty, D Aichele… - European Journal of …, 2018 - Elsevier
A new series of 2-amino-4-phenyl-6-hydroxy-7-alkyl-pyranobenzoquinones was
synthesized as ATP-competitive CK2 inhibitors. They were readily synthesized through a …

CX-4945, a selective inhibitor of casein kinase 2, synergizes with B cell receptor signaling inhibitors in inducing diffuse large B cell lymphoma cell death

E Mandato, SC Nunes, F Zaffino… - Current cancer drug …, 2018 - ingentaconnect.com
Background: Approximately one third of Diffuse Large B cell Lymphomas (DLBCL) are
refractory or relapse. Novel therapeutic approaches under scrutiny include inhibitors of B …

[HTML][HTML] Synergistic therapeutic effect of diethylstilbestrol and CX-4945 in human acute T-lymphocytic leukemia cells

JI Jung, KY Park, SA Kim, J Kim - Biomedicine & Pharmacotherapy, 2018 - Elsevier
Human acute T-lymphocytic leukemia (T-ALL) is one of the most commonly diagnosed
hematological disorders, and is characterized by poor prognosis and survival rate. Despite …

[HTML][HTML] In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute …

JI Jung, SY Kim, KY Park, K Sydara, SW Lee… - Biomedicine & …, 2018 - Elsevier
Since 1970, the isolated and identified components of Brucea javanica (L.) Merr. have been
known to contain anticancer effects, particularly antileukemic effect. In this study, the …

A Fragment-Based Drug Discovery Approach for the Development of Selective Inhibitors of Protein Kinase CK2

SL Mitchell - 2018 - repository.cam.ac.uk
Over the last twenty years, fragment-based drug discovery (FBDD) has emerged as a highly
successful way to provide lead compounds for subsequent optimisation into drug …

[PDF][PDF] Investigating MEK inhibition in the treatment of multiple myeloma

JAYJ HOCKING - 2018 - scholar.archive.org
Multiple myeloma is an incurable haematologic malignancy. Therapeutic advances continue
to improve overall survival, but there remains a need for the ongoing development of novel …